DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Sunday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $6.20 on Friday. The firm has a market capitalization of $127.53 million, a price-to-earnings ratio of -1.38 and a beta of 0.71. The business’s 50 day simple moving average is $4.45 and its 200-day simple moving average is $3.85. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $8.32.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.